Your session is about to expire
← Back to Search
Ketone Supplement
Exogenous Ketone Monoester for Type 2 Diabetes
N/A
Waitlist Available
Led By Jonathan Little, PhD
Research Sponsored by University of British Columbia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Have a type 2 diabetes diagnosis from a physician
Have stable use of glucose-lowering medications for at least 3 months
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1 through to day 10
Awards & highlights
Study Summary
This trial is testing whether ketone supplements can lower blood sugar and impact how the body's cells function.
Eligible Conditions
- Type 2 Diabetes
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ day 1 through to day 10
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1 through to day 10
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Glucose
Secondary outcome measures
Blood beta-hydroxybutyrate
Blood pressure
Body weight
+24 moreOther outcome measures
Cravings
Hunger and fullness cravings questionnaire
Supplement acceptability
+1 moreTrial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: ExperimentalExperimental Treatment1 Intervention
Participants will consume 15 g of an active oral exogenous ketone monoester supplement 15 minutes prior to each meal of the day for a 14-day period.
Pre-intervention (baseline) and post-intervention measurements will be obtained before and immediately after the 14-day period.
All meals will be provided throughout the supplementation period Participants will wear a continuous glucose monitor for the first 10 consecutive days during the supplementation period.
Group II: PlaceboPlacebo Group1 Intervention
Participants will consume a flavor-matched placebo drink and undergo the same procedures described in the Experimental Arm
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Exogenous Ketone Monoester
2022
N/A
~20
Find a Location
Who is running the clinical trial?
University of British ColumbiaLead Sponsor
1,407 Previous Clinical Trials
1,766,534 Total Patients Enrolled
Jonathan Little, PhDPrincipal InvestigatorUniversity of British Columbia- Okanagan
3 Previous Clinical Trials
190 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger